NCT07110051 Nalbuphine Versus Tramadol on Post Operative Analgesia in Abdominal Surgery on Pediatric Cancer Patient
| NCT ID | NCT07110051 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Institute, Egypt |
| Condition | Tramadol |
| Study Type | INTERVENTIONAL |
| Enrollment | 128 participants |
| Start Date | 2025-01-15 |
| Primary Completion | 2025-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 128 participants in total. It began in 2025-01-15 with a primary completion date of 2025-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In current study the investigators aim to compare between nalbuphine versus tramadol for post-operative pain control in abdominal surgeries in pediatric.
Eligibility Criteria
Inclusion Criteria: * Participants will be children aged 3-12 years * American society of anesthesia (ASA) classification I-III. * scheduled for elective Abdominal surgery under general anesthesia Exclusion Criteria: * child guardian refusal. * Allergy from Tramal or nalbuphine * Patient with previous chronic pain on opioids
Contact & Investigator
Reham mohamed gamal, MD
PRINCIPAL INVESTIGATOR
assistant professor
Frequently Asked Questions
Who can join the NCT07110051 clinical trial?
This trial is open to participants of all sexes, aged 3 Years or older, up to 12 Years, studying Tramadol. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07110051 currently recruiting?
Yes, NCT07110051 is actively recruiting participants. Contact the research team at norma.osama@nci.cu.edu.eg for enrollment information.
Where is the NCT07110051 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07110051 clinical trial?
NCT07110051 is sponsored by National Cancer Institute, Egypt. The principal investigator is Reham mohamed gamal, MD at assistant professor. The trial plans to enroll 128 participants.